May 17th 2024
New research has shown a link between children’s consumption of ultraprocessed foods and their risk of obesity and other cardiometabolic problems.
A Q&A on Smoking Cessation With E-Cigarettes, REDUCE-IT Trial Findings
March 30th 2020The American Journal of Managed Care® (AJMC® ) interviewed Martha Gulati, MD, cardiologist at Banner – University Medicine Heart Institute, on findings of eicosapentaenoic acid (EPA) levels in relation to cardiovascular outcomes and smoking cessation with e-cigarettes. These studies are part of the 2020 American College of Cardiology / World Congress of Cardiology Virtual Experience.
Read More
Dr Javed Butler Notes Subgroup Efficacy Differences of Vericiguat in VICTORIA Trial Findings
March 29th 2020In VICTORIA, patients within the first 3 quartiles of peptide elevation had results more impressive than the overall findings. However, patients with the highest quartile did not seem to benefit. This raises the question whether the sickest of the sick patients will benefit from vericiguat, said Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.
Watch
Dr Richard Kovacs on How ACC Is Leading the Charge for Credible Clinical Data Amid COVID-19
March 28th 2020We need more than ever credible clinical data both on the pandemic, but also how to understand how the pandemic’s going to affect patients in the cardiovascular field, said Richard Kovacs, MD, FACC, clinical cardiologist and president of the American College of Cardiology (ACC).
Watch
Dr Javed Butler on Key Takeaways of Vericiguat Found in VICTORIA Trial Participants With HFrEF
March 28th 2020Results from VICTORIA show vericiguat produced a 10% relative risk reduction in the highest-risk patients with heart failure. Study patients had about 3 times the health risk seen in recent heart failure trials, which showed higher relative risk reductions. However, VICTORIA saw a 4% absolute risk reduction, which is the same as the others, said Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.
Watch
What We're Reading: Probing Age Bias in Heart Care; Coronavirus Ship Deaths; Housing and Health
February 20th 2020A study found potential age bias in heart care for patients on different sides of their 80th birthday; 2 passengers from the Diamond Princess cruise ship die of coronavirus; California Governor Gavin Newsom outlined several mental health proposals to address homelessness in the state.
Read More
Economic Value of Transcatheter Valve Replacement for Inoperable Aortic Stenosis
Transcatheter aortic valve replacement for inoperable severe, symptomatic aortic stenosis will create significant social value in the next decade, mostly accruing to patients versus manufacturers.
Read More
In patients with heart failure, both with and without diabetes, dapagliflozin was shown to provide identical efficacy and possibly beneficial effects on the heart, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Watch
Migraine Attack in Response to Nitroglycerin Showed Greater Cardiovascular Responses, Study Finds
November 16th 2019A study investigating the cardiovascular responses to nitroglycerin in migraine found that migraineurs who developed a migraine-like attack in response to nitroglycerin demonstrated greater systemic cardiovascular responses compared with non-headache controls.
Read More
Dr Danielle Kirkman Explains How Exercise Testing in Patients With CKD Can Improve Care
November 8th 2019Because exercise capacity is known to be linked with several key outcome measures in patients with chronic kidney disease (CKD), routine exercise testing can help clinicians prescribe individualized exercise interventions, said Danielle Kirkman, PhD, assistant professor at Virginia Commonwealth University.
Watch
Cleveland Clinic Announces Top 10 Medical Innovations for 2020
October 25th 2019Cleveland Clinic announced the top 10 medical innovations for 2020, which details the medical advancements that have the potential power in transforming healthcare in the next year, at a multimedia presentation during the 2019 Medical Innovation Summit.
Read More
Study Examines Cardiovascular Disease Impact in Patients With COPD
September 28th 2019A recent study investigating the cardiovascular contribution to COPD symptoms and their relationship to a patient's diagnostic status found that patients with suspicious echocardiographic findings were undiagnosed and untreated.
Read More
Dapagliflozin Cuts Risk of CV Death, Worsening of Heart Failure 26%, Whether Diabetes Present or Not
September 1st 2019Dapagliflozin, sold by AstraZeneca as Farxiga, cut the risk of cardiovascular (CV) death and worsening of heart failure (HF) by 26% among patients with reduced ejection fraction alongside standard of care, according to results of a landmark phase 3 study presented Sunday at the European Society of Cardiology 2019 Congress. Results confirmed that the sodium glucose co-transporter 2 (SGLT2) inhibitor, already approved to treat type 2 diabetes (T2D), is just as effective in preventing CV death and HF events in patients who do not have T2D.
Read More
FDA Grants Fast Track Designation for Dapagliflozin to Prevent Kidney Failure
August 27th 2019Dapagliflozin’s fast track designation follows findings from last year’s DECLARE-TIMI trial, a cardiovascular outcomes trial that showed the drug’s significant impact on delaying the loss of kidney function and reducing hospitalization risk for heart failure.
Read More
Improving Heart Health at Age 50 Can Reduce Dementia Risk Later in Life
August 9th 2019People who have better cardiovascular health, as scored by the American Heart Association's Life's Simple 7, at age 50 have a lower risk of developing dementia over the next 25 years, according to a new study.
Read More
Rejected, Unfilled PCSK9 Inhibitor Prescriptions Linked to Higher Risk of Cardiovascular Events
July 23rd 2019Patients were 16% more likely to have a cardiovascular event if their prescription was rejected and 21% more likely to have a cardiovascular event if they did not fill their prescription.
Read More